Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 1/2011

01.01.2011 | General Gynecology

Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids

verfasst von: Efser Oztas, Gulay Kurtay

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the effects of raloxifene, on serum lipids and high-sensitivity C-reactive protein (hs-CRP) in healthy postmenopausal women.

Methods

We studied the effect of raloxifene, on serum lipids and hs-CRP in 85 healthy postmenopausal women. Participants were randomly assigned to 60 mg daily raloxifene (43 subjects) for 6 months; the rest of the subjects were in the control group. Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglyceride and hs-CRP levels were measured at baseline and at the sixth month in both groups.

Results

Raloxifene treatment resulted in a 26% reduction in serum hs-CRP concentrations at the sixth month, compared with the baseline levels (P < 0.05). At the sixth month, TC and LDL-C levels were significantly reduced by 60 mg daily raloxifene (6.8 and 5.6%, respectively) when compared with both the baseline levels and the control group.

Conclusion

The results of our study showed that raloxifene at a dose of 60 mg daily reduces serum TC, LDL-C and hs-CRP levels significantly in healthy postmenopausal women. According to the results of the current study, we suggest that raloxifene may have a favorable effect on the prevention of cardiovascular disease in healthy postmenopausal women.
Literatur
1.
Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of Framingham population. Am J Heart 111:383–390CrossRef
2.
Gohlke-Barwolf C (2000) Coronary artery disease—is menopause a risk factor? Basic Res Cardiol 95(Suppl 1):77–83CrossRef
3.
Heart, Estrogen/progestin Replacement Study (HERS) Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280(7):605–613CrossRef
4.
Heart, Estrogen/progestin Replacement Study (HERS) Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1):49–57CrossRef
5.
Cherry N, Gilmour K, Hannaford P (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360(9350):2001–2008CrossRefPubMed
6.
Writing Group For The Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRef
7.
The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRef
8.
9.
Hanson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695CrossRef
10.
Fan J, Watanabe T (2003) Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 10:63–71PubMed
11.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1999) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336(14):973–979CrossRef
12.
Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97(20):2007–2011PubMed
13.
Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed
14.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2000) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565CrossRef
15.
Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21–29PubMed
16.
Saitta A, Morabito N, Frisina N (2001) Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev 19(1):57–74CrossRefPubMed
17.
Walsh BW, Cox DA, Sashegyi A (2001) Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88(7):825–828CrossRefPubMed
18.
Yasui T, Uemura H, Hyodo S, Yamada M, Yamamoto S, Maegawa M, Tsuchiya N, Noguchi M, Yuzurihara M, Kase Y, Irahara M (2009) Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women. Atherosclerosis 204(2):471–475CrossRefPubMed
19.
Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287(7):847–857CrossRefPubMed
20.
Griffiths KA, Sader MA, Skilton MR (2003) Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 42(4):698–704CrossRefPubMed
21.
Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM (2008) Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 6(6):928–934CrossRefPubMed
22.
Blumenthal RS, Baranowski B, Dowsett SA (2004) Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 147(5):783–789CrossRefPubMed
23.
Barrett-Connor E, Ensrud KE, Harper K (2003) Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 25(3):919–930CrossRefPubMed
24.
De Leo W, la Marca A, Morgante G (2001) Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184(3):350–353CrossRefPubMed
25.
Walsh BW, Kuller LH, Wild RA (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279(18):1445–1451CrossRefPubMed
26.
Johnston CC, Bjarnason NH, Cohen FJ (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160(22):3444–3450CrossRefPubMed
27.
Anderson PW, Cox DA, Sashegyi A (2001) Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 39(1):71–77CrossRefPubMed
28.
Delmas PD, Bjarnason NH, Mitlak BH (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337(23):1641–1647CrossRefPubMed
29.
Piperi C, Kalofoutis C, Lagogianni I, Troupis G, Kalofoutis A (2004) Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women. Mol Cell Biochem 261(1–2):71–75CrossRefPubMed
30.
Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137CrossRefPubMed
31.
Toss H, Lindahi B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive proteinlevels in unstable coronary artery disease. Circulation 96:4204–4210PubMed
32.
Tracy RP, Lemaitre RN, Psaty BM (1997) Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol 17:1121–1127PubMed
33.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMed
34.
Herrington DM, Brosnihan KB, Pusser BE (2001) Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 86(9):4216–4222CrossRefPubMed
35.
Walsh BW, Paul S, Wild RA (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85(1):214–218CrossRefPubMed
36.
Blum A, Cannon RO (2001) Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men. Ann N Y Acad Sci 949:168–174CrossRefPubMed
37.
de Valk-de Roo GW, Stehouwer CD, Meijer P (1999) Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19(12):2993–3000PubMed
Metadaten
Titel
Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids
verfasst von
Efser Oztas
Gulay Kurtay
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-009-1292-9

Weitere Artikel der Ausgabe 1/2011

Archives of Gynecology and Obstetrics 1/2011 Zur Ausgabe

Materno-Fetal Medicine

Misoprostol and termination of pregnancy: is there a need for ultrasound screening in a general population to assess the risk for adverse outcome in cases of uterine anomaly?

Letter to the Editor

Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib

Materno-fetal Medicine

Effect of pre-pregnancy body mass index on adverse pregnancy outcome in north of China

Acknowledgement to Referees

Reviewers 2010

Reproductive Medicine

Reactive oxygen species measurement in neat and washed semen: comparative analysis and its significance in male infertility assessment

Materno-fetal Medicine

Maternal satisfaction and acceptability of foetal electrocardiographic (STAN®) monitoring system

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise